Carotid sparing in t1-t2 no glottic cancer using helical tomotherapy

Détails

ID Serval
serval:BIB_CD670E5ED273
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Carotid sparing in t1-t2 no glottic cancer using helical tomotherapy
Titre de la conférence
15th Annual Meeting of the Scientific Association of Swiss Radiation Oncology
Auteur⸱e⸱s
Cosinschi A., Khanfir K., Boujelbene N., Herrera F., Pachoud M., Matzinger O., Ozsahin M.
Adresse
Geneva, Switzerland, March 31-April 2, 2011
ISBN
0179-7158
Statut éditorial
Publié
Date de publication
2011
Peer-reviewed
Oui
Volume
187
Série
Strahlentherapie und Onkologie
Pages
536
Langue
anglais
Notes
Publication type : Meeting Abstract
Résumé
Objective: To study the dosimetric properties and clinical implementation of a carotid dose sparing irradiation protocol using helical Tomotherapy in early stage laryngeal cancer.Materials and Methods: We have developed a simple treatment planning algorithm for carotid sparing. We have compared carotid and critical organ doses and planned target volume (PTV) dose with our standard laryngeal irradiation protocol. Dose constraints were the following: maximum point dose to the carotids <35 Gy, to the spinal cord <30 Gy, and PTV was covered at >95% of the prescribed dose (70 Gy in 2 Gy per fraction). A daily megavoltage CT was done to account for patient movement and anatomy modification. To date, 7 patients have been treated with this protocol in our department.Results: Our early results showed a significant reduction in the carotid dose with an average maximum dose of 35.8 Gy. The average maximum spinal cord dose was 25.8 Gy. PTV was covered without important "hot spots". Average maximum dose in the PTV was 74.1 Gy with an average absolute maximum dose of 75.2 Gy. To date, the clinical outcomes have been excellent.Conclusion: Helical Tomotherapy allows a significant decrease of carotid dose without dangerous spinal cord overdose. There was no important overdose in the PTV that can potentially increase the late complication risks. Daily control imaging brings added security especially when working with such high-dose gradients. We think further studies and longer follow-up are needed to investigate the clinical outcomes such as the local control rate and the vascular late toxicities.
Mots-clé
,
Web of science
Création de la notice
23/09/2011 14:08
Dernière modification de la notice
20/08/2019 15:48
Données d'usage